| 2.07 0.14 (7.25%) | 01-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.44 |
1-year : | 2.85 |
| Resists | First : | 2.08 |
Second : | 2.44 |
| Pivot price | 1.89 |
|||
| Supports | First : | 1.85 |
Second : | 1.71 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 1.87 |
| MA(100) : | 1.67 |
MA(250) : | 1.49 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83 |
D(3) : | 75.1 |
| RSI | RSI(14): 63.7 |
|||
| 52-week | High : | 2.48 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AKBA ] has closed Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.11 |
| Low: | 1.9 - 1.91 | 1.91 - 1.92 |
| Close: | 2.05 - 2.07 | 2.07 - 2.08 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fri, 17 Jan 2025
Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat
Fri, 17 Jan 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Increase in Short Interest - MarketBeat
Fri, 17 Jan 2025
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Tue, 14 Jan 2025
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mon, 13 Jan 2025
Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan
Mon, 13 Jan 2025
Akebia Therapeutics Announces Multiple Positive Business Updates - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 218 (M) |
| Shares Float | 198 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 27.3 (%) |
| Shares Short | 14,070 (K) |
| Shares Short P.Month | 11,960 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.24 |
| Profit Margin | -27.1 % |
| Operating Margin | -33.5 % |
| Return on Assets (ttm) | -9.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -11 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.77 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -9.41 |
| PEG Ratio | 0 |
| Price to Book value | -8.63 |
| Price to Sales | 2.65 |
| Price to Cash Flow | -11.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|